HALO - Company ID 0001159036
HALOZYME THERAPEUTICS, INC. (HALO) reported net income of $316.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $316.89M | -28.6% |
| FY 2024 | $444.09M | +57.7% |
| FY 2023 | $281.59M | +39.3% |
| FY 2022 | $202.13M | -49.8% |
| FY 2021 | $402.71M | +212.0% |
| FY 2020 | $129.09M | +278.7% |
| FY 2019 | -$72.24M | +10.1% |
| FY 2018 | -$80.33M | -227.6% |
| FY 2017 |
HALOZYME THERAPEUTICS, INC. (HALO) reported net income of $316.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, HALOZYME THERAPEUTICS, INC.'s net income grew from -$19.77M to $316.89M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $62.97M |
| +161.1% |
| FY 2016 | -$103.02M | -219.6% |
| FY 2015 | -$32.23M | +52.9% |
| FY 2014 | -$68.38M | +18.1% |
| FY 2013 | -$83.48M | -55.9% |
| FY 2012 | -$53.55M | -170.9% |
| FY 2011 | -$19.77M | - |